8-K: SeaStar Medical Reports Strong 2025 Growth, Adult AKI Trial Progress

SeaStar Medical announced significant revenue growth and clinical trial advancements for its life-saving therapies in its Q4 and full-year 2025 financial results.

Summary

• Net revenue for the fourth quarter of 2025 was approximately $420 thousand, a substantial increase from $67 thousand in the same period of 2024.
• Full-year 2025 net revenue reached approximately $1.2 million, up from $135 thousand in 2024, reflecting the first full year of QUELIMMUNE product sales.
• The net loss for Q4 2025 improved to approximately $2.9 million ($0.80 per share) from $4.4 million ($8.98 per share) in Q4 2024.
• The full-year 2025 net loss significantly decreased to approximately $12.2 million ($5.86 per share) from $24.8 million ($66.33 per share) in 2024.
• Cash on hand as of December 31, 2025, was $12.0 million, a substantial increase from $1.8 million at the end of 2024.
• The company expanded its QUELIMMUNE therapy customer base by adding 13 new top-rated children's hospitals, bringing the total to 16.
• Enrollment was completed in the FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry, with 50 patients enrolled.
• The NEUTRALIZE-AKI pivotal trial for adult patients with AKI achieved over 50% enrollment, with 181 of 339 patients enrolled to date.
• Efforts were initiated for a modular Premarket Application (PMA) submission to potentially expedite FDA review for the adult AKI indication.
• The pipeline was expanded with the initiation of the NEUTRALIZE-CRS clinical trial for chronic heart failure with cardiorenal syndrome, expected to enroll 20 patients.
• The company's balance sheet improved with approximately $23.9 million in capital added during 2025 and a $3.1 million reduction in operating liabilities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, reflecting strong revenue growth, improved financial health, and significant progress in key clinical trials, particularly the adult AKI pivotal study, which holds substantial future revenue potential.

Positives

• Net revenue for Q4 2025 increased significantly to $420 thousand from $67 thousand in Q4 2024, driven by QUELIMMUNE product sales and SCD sales for research.
• Full-year 2025 net revenue grew substantially to $1.2 million from $135 thousand in 2024, marking the first full year of commercial sales.
• Net loss decreased for both Q4 2025 ($2.9 million vs $4.4 million) and full-year 2025 ($12.2 million vs $24.8 million), indicating improved financial performance.
• Cash balance improved dramatically to $12.0 million at year-end 2025 from $1.8 million at year-end 2024, strengthening liquidity.
• Successful expansion of the QUELIMMUNE customer base to 16 top-rated children's hospitals, adding 13 new sites.
• Completion of enrollment in the FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry, with preliminary data showing 76% survival at 60 days and 71% at 90 days, validating a nearly 50% reduction in loss of life compared to historical data.
• Achieved a critical milestone of over 50% enrollment (181 of 339 patients) in the NEUTRALIZE-AKI pivotal trial for adult AKI.
• Initiated modular PMA submission efforts for adult AKI, potentially speeding FDA review due to Breakthrough Device Designation.
• Expanded the pipeline with the initiation of the NEUTRALIZE-CRS clinical trial for chronic heart failure with cardiorenal syndrome, which also received Breakthrough Device Designation.
• Gross profit margin for QUELIMMUNE sales in Q4 2025 was greater than 90%.

Negatives

• The company continues to operate at a net loss, reporting $2.9 million for Q4 2025 and $12.2 million for the full year 2025.
• Despite revenue growth, total revenue remains relatively low for a commercial-stage company, indicating early market penetration.
• There was a significant increase in weighted-average shares outstanding (from 0.5 million to 3.6 million in Q4, and 0.4 million to 2.1 million for full year), indicating shareholder dilution.

Risks

• Risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates.
• Risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• Risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators.
• Risk that SeaStar Medical may never achieve or sustain profitability.
• Risk that SeaStar Medical may not be able to secure additional financing on acceptable terms.
• Risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services.
• Risk that SeaStar Medical is unable to secure or protect its intellectual property.

Future Outlook

SeaStar Medical anticipates broadening QUELIMMUNE adoption to 15 additional top-ranked children's medical centers in 2026, aiming to achieve approximately $2 million in net product revenue. The company expects to complete enrollment in the NEUTRALIZE-AKI pivotal trial for adult AKI around the end of 2026 and begin modular Premarket Application (PMA) submissions to the FDA to facilitate review. Furthermore, it plans to evaluate broader applicability of the SCD therapy through the conduct of a pivotal trial for patients with acute chronic heart failure (CHF) with cardiorenal syndrome (CRS) awaiting LVAD implantation and explore rapid regulatory pathways for commercialization of the SCD therapy for other destructive hyperinflammatory conditions, seeking additional Humanitarian Use and Breakthrough Device Designations.

Management Comments

• "In 2025, we broadened our customer base of top-ranked childrens hospitals, continued enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and advanced our pipeline with the initiation of the cardio-renal clinical trial of our selective cytopheretic device (SCD) therapy." Eric Schlorff, CEO.
• "We move into 2026 with strong momentum and key value creating milestones that will not only impact our success but also advance our mission to bring a potential life-saving therapy to patients who would otherwise have little hope of survival." Eric Schlorff, CEO.
• "I want to acknowledge the dedication and tenacity of our team for surpassing the 50% enrollment milestone of the NEUTRALIZE-AKI trial. Every day that we activate a new clinical site, or enroll another subject, brings us closer to potentially helping as many patients in the ICU as possible defeat destructive hyperinflammation." Eric Schlorff, CEO.
• "To that end, we are already preparing portions of the Premarket Application (PMA) for modular submission to better facilitate the FDA review process for the adult AKI indication. The adult AKI patient population is approximately 50 times larger than the pediatric AKI market in the U.S. alone. It is the core market that we believe will drive significant revenue expansion for the company." Eric Schlorff, CEO.
• "Our success in building the QUELIMMUNE market now will provide critical support for that future revenue opportunity, as we anticipate continued strong adoption of QUELIMMUNE in 2026 and beyond." Eric Schlorff, CEO.

Industry Context

StockSavvy.ai notes that SeaStar Medical operates in the critical care medical device sector, focusing on acute organ failure, a high-need area with significant unmet medical needs, particularly for conditions like Acute Kidney Injury (AKI) and Cardiorenal Syndrome (CRS) where effective treatments are limited. The company's strategy of targeting ultra-rare pediatric AKI first, then expanding to the much larger adult AKI market, aligns with a common biotech commercialization pathway. The multiple Breakthrough Device Designations underscore the potential for these therapies to address severe, life-threatening conditions, positioning SeaStar Medical as a key innovator in this specialized field.

Comparison to Industry Standards

• The 77% survival rate in QUELIMMUNE treated patients versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data, is a strong clinical outcome for a life-threatening condition.
• Preliminary outcomes from the QUELIMMUNE SAVE Registry showing a 76% survival rate at Day 60 and 71% at Day 90 further validate these results, aligning with the registration study reported in Kidney Medicine.
• The adult AKI patient population is approximately 50 times larger than the pediatric AKI market in the U.S. alone, indicating a substantial market opportunity if the NEUTRALIZE-AKI trial is successful and approved.
• Breakthrough Device Designation by the FDA for multiple indications (adult AKI, CHF with CRS) is a significant regulatory achievement, indicating the potential for these devices to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases compared to existing options.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth, pipeline advancement, and improved financial position, but also dilution from increased shares outstanding.
• Patients (Pediatric AKI): Continued access to QUELIMMUNE therapy, with further validation of its life-saving potential and expanded availability.
• Patients (Adult AKI, CHF with CRS): Hope for new treatment options as clinical trials progress and regulatory pathways are pursued for severe, life-threatening conditions.
• Healthcare Providers: Expansion of QUELIMMUNE availability to more children's hospitals, offering a new treatment option for critically ill pediatric AKI patients.

Next Steps

• Broaden QUELIMMUNE adoption to include 15 additional top-ranked children's medical centers in 2026, more than doubling the total number of sites.
• Achieve approximately $2 million in net product revenue in 2026.
• Advance the SCD therapy for the adult AKI indication through completion of enrollment in the NEUTRALIZE-AKI pivotal trial around the end of 2026.
• Begin submission of relevant PMA modules to the FDA to facilitate the PMA review and approval process for adult AKI.
• Evaluate broader applicability of the SCD therapy through the conduct of a pivotal trial in patients with acute CHF with CRS awaiting LVAD implantation (NEUTRALIZE-CRS trial).
• Explore rapid regulatory pathways to commercialization of the SCD therapy for numerous destructive hyperinflammatory conditions, seeking additional Humanitarian Use and Breakthrough Device Designations.
• Report the 28-day safety results from the SAVE Registry to the FDA upon completion of its analysis of the data.

Key Dates

Recommendation

While SeaStar Medical demonstrated strong revenue growth, improved financials, and significant clinical trial progress, the company remains unprofitable and relies heavily on future regulatory approvals and commercialization success for its adult AKI indication. The substantial increase in shares outstanding indicates dilution. The positive momentum warrants a "hold" as investors await further clinical trial results and FDA approvals for the larger adult market, which are critical for long-term profitability.

Keywords

Acute Kidney Injury, AKI, QUELIMMUNE, SCD therapy, Selective Cytopheretic Device, Sepsis, Renal Replacement Therapy, RRT, Hyperinflammation, Pediatric AKI, Adult AKI, NEUTRALIZE-AKI, NEUTRALIZE-CRS, Cardiorenal Syndrome, CHF, LVAD, FDA Breakthrough Device, PMA, Clinical Trials, Organ Failure, Healthcare, Medical Devices, Biotechnology